PLNH (Planet 13 Holdings) Debt-to-Equity: 1.24 (As of Mar. 2026) — 490% Above Median


PLNH Planet 13 Holdings Inc PLNH
31 GF Score
Price $0.13
GF Value $0.30
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Planet 13 Holdings Debt-to-Equity?

Planet 13 Holdings PLNH +1.50% 31 Debt-to-Equity is 1.24 as of Mar. 2026, which is 490% above its 10-year median of 0.21. GuruFocus rates PLNH with a GF Score™ of 31/100 and a GF Value™ of $0.30 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 812 Drug Manufacturers companies, Planet 13 Holdings ranks worse than 89.78% on this metric.

Planet 13 Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $11.21 Mil. Planet 13 Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $42.89 Mil. Planet 13 Holdings's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $43.73 Mil. Planet 13 Holdings's debt to equity for the quarter that ended in Mar. 2026 was 1.24.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Planet 13 Holdings's Debt-to-Equity or its related term are showing as below:

PLNH' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.31   Med: 0.21   Max: 1.24
Current: 1.24

During the past 10 years, the highest Debt-to-Equity Ratio of Planet 13 Holdings was 1.24. The lowest was -0.31. And the median was 0.21.

PLNH's Debt-to-Equity is ranked worse than
89.78% of 812 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs PLNH: 1.24

Planet 13 Holdings  (OTCPK:PLNH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Planet 13 Holdings Debt-to-Equity Related Terms


Planet 13 Holdings Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Planet 13 Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Planet 13 Holdings Debt-to-Equity Chart

Planet 13 Holdings Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.15 0.25 0.51 1.06

Planet 13 Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.60 1.08 1.06 1.24

PLNH vs ZTS, UTHR: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Planet 13 Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Planet 13 Holdings Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Planet 13 Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Planet 13 Holdings's Debt-to-Equity falls into.


PLNH
31GF Score
Planet 13 Holdings Inc PLNH
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Planet 13 Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Planet 13 Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Planet 13 Holdings's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 1.24 mean?
Planet 13 Holdings (PLNH) has a Debt-to-Equity of 1.24 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Planet 13 Holdings and its competitors. This is 490% above median its historical median of 0.21. According to the industry distribution chart, Planet 13 Holdings ranks #729 out of 812 companies in the Drug Manufacturers industry, placing it in the top 89.8%.
Is Planet 13 Holdings' Debt-to-Equity too high?
Planet 13 Holdings' current Debt-to-Equity of 1.24 is 490% above median its 10-year median of 0.21. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Planet 13 Holdings' value of 1.24 is 359.3% above this industry median. Based on the distribution chart, Planet 13 Holdings ranks #729 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Planet 13 Holdings has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Planet 13 Holdings' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Planet 13 Holdings ranks #729 out of 812 companies for Debt-to-Equity. This places Planet 13 Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Planet 13 Holdings' value of 1.24 is 359.3% above this benchmark. While the company's 10-year median is 0.21 vs. the industry median of 0.27, Planet 13 Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Planet 13 Holdings's current Debt-to-Equity of 1.24 is 359.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Planet 13 Holdings and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Planet 13 Holdings's current Debt-to-Equity is 1.24, which is 490% above median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Planet 13 Holdings stock overvalued right now?
Based on GuruFocus' analysis, Planet 13 Holdings (PLNH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.30, compared to a current price of $0.13 — trading 57.2% below its estimated fair value. The current Debt-to-Equity is 1.24, which is 490% above median its 10-year median of 0.21 and 359.3% above the Drug Manufacturers industry median of 0.27. Planet 13 Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Planet 13 Holdings (PLNH), the current Debt-to-Equity is 1.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Planet 13 Holdings (PLNH) Overvalued in 2026?

Based on GuruFocus' analysis, Planet 13 Holdings stock appears to be undervalued. The current stock price of $0.13 is trading 57.2% below its estimated GF Value™ of $0.30. GuruFocus considers Planet 13 Holdings to be Possible Value Trap.

Key valuation signals for PLNH:

  • Debt-to-Equity: 1.24 (490% above median its 10-year median of 0.21)
  • GF Value™: $0.30 vs. price of $0.13 (57.2% below fair value)
  • GF Score™: 31/100 with 7 warning signs
  • Industry Position: 359.3% above the Drug Manufacturers median (#729 of 812)

No single metric tells the full story. See the PLNH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Planet 13 Holdings Business Description

Other Exchanges Y7Q:GermanyPLTH:Canada
Address 2548 West Desert Inn Road, Suite 100, Las Vegas, NV, USA, 89109
Planet 13 Holdings Inc a vertically integrated cultivator and provider of cannabis and cannabis-infused products in the States of Nevada and California, with retail cannabis operations in Illinois. The company owns and manufactures cannabis products under the following brands: HaHa (gummies and beverages), Dreamland (chocolates), TRENDI (vapes and concentrates), Medizin (flower, vapes, concentrates), Leaf and Vine (vapes).
31GF Score

Get the complete analysis for PLNH

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$0.30
GF Value